MedPath

VALERIO THERAPEUTICS

🇫🇷France
Ownership
-
Employees
-
Market Cap
-
Website

Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary

Phase 2
Completed
Conditions
Carcinoma of Unknown Primary
Interventions
First Posted Date
2009-04-01
Last Posted Date
2015-07-28
Lead Sponsor
Valerio Therapeutics
Target Recruit Count
89
Registration Number
NCT00873119
Locations
🇺🇸

Florida Cancer Specialists, Fort Myers, Florida, United States

🇺🇸

Northwest Georgia Oncology Centers, Marietta, Georgia, United States

🇺🇸

Baton Rouge Medical Center, Baton Rouge, Louisiana, United States

and more 20 locations

Phase 3 Clinical Study for the Treatment of Cold Sore

Phase 3
Completed
Conditions
Herpes Labialis
Interventions
First Posted Date
2008-10-09
Last Posted Date
2012-12-21
Lead Sponsor
Valerio Therapeutics
Target Recruit Count
1727
Registration Number
NCT00769314
Locations
🇺🇸

Radiant Research, Inc.,, Tucson, Arizona, United States

🇺🇸

Dermatology Private Practice, San Fransisco, California, United States

🇺🇸

Front Range Clinical Research, Wheat Ridge, Colorado, United States

and more 46 locations

Efficacy of TopotectTM (Dexrazoxane) for Accidental Extravasation of Anthracyclines

Phase 2
Completed
Conditions
Anthracycline Extravasation
First Posted Date
2007-10-24
Last Posted Date
2015-10-21
Lead Sponsor
Valerio Therapeutics
Target Recruit Count
23
Registration Number
NCT00548561
Locations
🇩🇰

Aalborg Hospital South, Aalborg, Denmark

🇩🇰

Rigshospitalet, Copenhagen, Denmark

🇩🇰

Herlev County Hospital, Herlev, Denmark

and more 6 locations

A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines

Phase 2
Completed
Conditions
Extravasation
First Posted Date
2007-10-24
Last Posted Date
2015-10-21
Lead Sponsor
Valerio Therapeutics
Target Recruit Count
57
Registration Number
NCT00548704
Locations
🇩🇰

Aalborg Hospital South, Aalborg, Denmark

🇩🇰

Aarhus County Hospital, Aarhus, Denmark

🇩🇰

Aarhus Municipality Hospital, Aarhus, Denmark

and more 30 locations

A Phase I Dose Finding Study of APO010 in Patients With Solid Tumors

Phase 1
Completed
Conditions
Cancer
Interventions
First Posted Date
2007-02-21
Last Posted Date
2015-09-17
Lead Sponsor
Valerio Therapeutics
Target Recruit Count
26
Registration Number
NCT00437736
Locations
🇨🇭

Oncology Institute of Southern Switzerland, Hospital of Bellinzona, Bellinzona, Switzerland

🇨🇭

Multidisciplinary Oncology Center, Cantonal University Hospital of Vaud, Lausanne, Switzerland

A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL

Phase 1
Completed
Conditions
B-cell Chronic Lymphocytic Leukemia
Interventions
First Posted Date
2007-02-14
Last Posted Date
2015-09-23
Lead Sponsor
Valerio Therapeutics
Target Recruit Count
10
Registration Number
NCT00435084
Locations
🇬🇧

Department of Heamtology, Cardiff and Vale NHS Trust, Cardiff, United Kingdom

🇬🇧

Department of Heamtology, Leeds General Infirmary, Leeds, United Kingdom

🇬🇧

Department of Heamtology, Bart's and the London NHS Trust, London, United Kingdom

and more 1 locations

A Study to Assess APO866 for the Treatment of Advanced Melanoma

Phase 2
Completed
Conditions
Melanoma
Interventions
First Posted Date
2007-02-07
Last Posted Date
2015-09-29
Lead Sponsor
Valerio Therapeutics
Target Recruit Count
25
Registration Number
NCT00432107
Locations
🇦🇹

Department of Dermatology, Medical University Graz, Graz, Austria

🇫🇷

Department of Dermatology, Hopital Henri Modor, Créteil, France

🇫🇷

Department of Dermatologie, Hotel Dieu, Nantes, France

and more 3 locations

A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma

Phase 2
Completed
Conditions
Cutaneous T-cell Lymphoma
Interventions
First Posted Date
2007-02-06
Last Posted Date
2015-07-08
Lead Sponsor
Valerio Therapeutics
Target Recruit Count
25
Registration Number
NCT00431912
Locations
🇦🇹

Department of Dermatology, Medical University Graz, Graz, Austria

🇫🇷

Deapartment of Dermatology, Créteil, France

🇫🇷

department of Dermatologie, Hotel Dieu, Nantes, France

and more 2 locations

A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma

Phase 2
Terminated
Conditions
Multiple Myeloma
First Posted Date
2007-02-05
Last Posted Date
2015-07-08
Lead Sponsor
Valerio Therapeutics
Target Recruit Count
4
Registration Number
NCT00431340
Locations
🇺🇸

Oncotherapeutics, West Hollywood, California, United States

🇺🇸

Center for cancer and blood disorders, Bethesda, Maryland, United States

🇺🇸

Baylor University Medical Center, Dallas, Texas, United States

A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment

Phase 1
Completed
Conditions
Ovarian Cancer
Epithelial Ovarian Cancer
Bladder Cancer
Fallopian Tube Cancer
Interventions
First Posted Date
2007-01-15
Last Posted Date
2015-07-28
Lead Sponsor
Valerio Therapeutics
Target Recruit Count
80
Registration Number
NCT00421889
Locations
🇺🇸

Gynecologic Oncology Associates, Newport Beach, California, United States

🇺🇸

Research Facility, Orlando, Florida, United States

🇺🇸

Hematology and Oncology Specialists, LLC, Covington, Louisiana, United States

and more 8 locations
© Copyright 2025. All Rights Reserved by MedPath